BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, January 12, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Jan. 6, 2021

View Archived Issues
Merger-arrows-black-white.png

Pixium Vision, Second Sight Medical set to combine

Pixium Vision SA and Second Sight Medical Products Inc. have inked a definitive agreement through which the former will become the controlling shareholder of the newly combined company. The transaction also will result in the creation of a new entity that will focus on cortical stimulation through Orion. Second Sight is developing that product, which bypasses the diseased eye and could provide a new form of vision. Read More
respiratory-lung-COVID-19-coronavirus.png

Nextgen launches trial for rapid breath test to measure COVID-19 vaccine efficacy

Nextgen Biomed Ltd. has begun a clinical trial of a breath test to monitor antibody levels in individuals vaccinated against COVID-19. Be'er Ya'akov, Israel-based Shamir Medical Center authorized the trial for test developer Scent Medical Technologies Ltd. (Scentech Medical), which is in the midst of merging with Nextgen. The merged company will be called Scentech Medical. Read More
covid-19-coronavirus-US-digital.png

Stenzel: FDA not in a hurry to address EUA conversion due to persistence of pandemic

The U.S. FDA is actively working on guidance for conversion of emergency use authorizations (EUAs) to conventional premarket review programs, but the FDA’s Tim Stenzel said he does “not perceive a need to rush to convert EUAs” because of the volume of EUA applications, and because he does not expect the public health emergency “to end anytime soon.” Read More
Flag of Australia, sky background

Australia’s TGA approves Orthocell’s Celgro regenerative collagen medical device

PERTH, Australia – Perth-based regenerative medicine company Orthocell Ltd. received marketing clearance from Australia’s Therapeutic Goods Administration (TGA) for its Celgro collagen medical device for dental guided bone and soft tissue regeneration applications. The approval validates the Celgro platform technology and clears the way for further approvals in nerve and tendon repair, Orthocell CEO Paul Anderson told BioWorld. Read More
Product image

Quantitative transmission ultrasound shows promise as mammography alternative

A new imaging technology that uses transmission ultrasound to provide a 3D image of breast tissue outperformed traditional digital mammography in a recent retrospective analysis. The study findings could set the stage for the U.S. FDA to clear the technology for breast cancer screening in young, high-risk women. Read More

Appointments and advancements for Jan. 6, 2021

New hires and promotions in the med-tech industry, including: Dermtech, Halo Health, Nanomedic Technologies. Read More

Financings for Jan. 6, 2021

Med-tech firms raising money in public or private financings, including: Adapthealth, Corwave, Neogenomics, Titan Medical. Read More

In the clinic for Jan. 6, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Mitre Medical, Neurolief, Sensory Cloud. Read More

Other news to note for Jan. 6, 2021

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Advanced Oncotherapy, Apex Family Medical, Bioclinica, Biodesix, Bio-Techne, Biotheranostics, Bioventrix, Carmat, Change Healthcare, Cssi Lifesciences, Diamedcare, Fathom Consulting, Fresenius Kabi, Helix Opco, Helius Medical Technologies, Hologic, Illumina, Medacuity, Monteris Medical, Nephros, Novasep, Optimuminsight, Pointclickcare, Rewalk Robotics, Saliency, Sartorius, Scaleready, Seegene, Sequans Communications, Skylight Health, Tonic Bioventures, Withings, Valgenesis. Read More

Regulatory actions for Jan. 6, 2021

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Northstar Medical Radioisotopes, Spectrum Solutions, Ultromics. Read More

Regulatory front for Jan. 6, 2021

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: FDA grants EUA to Quanterix for Simoa test; EC investing in startups; Alternatives to animal testing a challenge; USPTO seeks more uniformity between PTAB, courts; NICE nods to Olympus Plasma for BPH. Read More

BioWorld MedTech’s Orthopedics Extra for Jan. 6, 2021

Keeping you up to date on recent developments in orthopedics, including: Discovery of aging mechanism for hematopoietic stem cells; Long-term study finds dozens of new genetic markers associated with lifetime bone growth; Living alone may increase risk of dying after hip fracture; Bone fracture risk may increase when critical enzymatic processes decline. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 9, 2026.
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld Science
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • CAR T cell attacking cancer cells

    Development and characterization of anti-CD19 in vivo CAR T therapy

    BioWorld Science
    Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
  • Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

    BioWorld Science
    The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing